MedTrace Logo

Can Blood Panels Provide Early Warning of Bleeding in Patients on ECMO?

NCT04478136 · Status: WITHDRAWN · Type: OBSERVATIONAL

Last updated 2022-04-28

No results posted yet for this study

Summary

This is a prospective, observational study of 60 adult patients anticoagulated with bivalirudin for extracorporeal membrane oxygenation (ECMO). The study aims to identify the most precise early warning blood test or panel of blood tests to predict bleeding in patients on bivalirudin/ECMO. The project will involve comparing currently used blood tests with an extended panel of coagulation and metabolic blood tests with the aim of early warning of impending bleeding to allow intervention in the form of adjusted bivalirudin dose, modification of other risk factors, or transfusion with hemostatic products targeted to documented coagulation test abnormalities.

Conditions

Interventions

DIAGNOSTIC_TEST

Blood test of factor levels

Blood draw from central line to check coagulation factors

Sponsors & Collaborators

  • Montefiore Medical Center

    lead OTHER

Principal Investigators

  • Kiri Mackersey, MBChB · Albert Einstein College

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-12-01
Primary Completion
2022-12-01
Completion
2023-06-01

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04478136 on ClinicalTrials.gov